Stryker Corp. (SYK) EQUITY RESEARCH AMERICAS. Recon Strong in 4Q; Stability Expected for HOLD Price target $ Price $96.
|
|
- Lesley Houston
- 5 years ago
- Views:
Transcription
1 COMPANY NOTE USA Healthcare Medical Supplies & Devices Stryker Corp. (SYK) Recon Strong in 4Q; Stability Expected for 2016 Key Takeaway SYK 4Q results showed a surge in recon where a good domestic volumes, innovation (3D & Mako) and perhaps share gains, drove strong hip and knee growth. Initial 2016 guidance calls for much of the same, with +5-6% cc revenue growth generally ahead of expectations and at the upper-end of largecap medtech. The strong underlying performance seems sufficiently priced in, keeping us at Hold. Recon surge driven by good volumes and innovation; less so from market disruption. The key highlight out of Stryker s 4Q results was a surge in core orthopedics which increased to +7% cc up from the low single digits through much of Within recon, US knee growth was the biggest highlight, growing +9.1% cc (+5.7% last Q), and supported in part by an uptake of titanium 3D products including a tibial baseplate for cementless knees and 3D cones for revision knees, both launched in Volumes also remain healthy. While strong US recon prints from Depuy (JNJ, $101.18, Hold) and SYK point to some benefit from possible sales force disruptions at Zimmer (ZBH, $101.74, Buy), both pointed to stable markets and product innovation while playing down share gains. MAKO driving hips with knees to follow in Some signs of marginal returns on the $1.5bn MAKO Surgical acquisition developed in 4Q with robot placements increasing to 31 (versus 17 in 3Q) and ending the year at 72 globally. More importantly, MAKO is now driving implant volumes following the launch of its total hip system on the robot in early FDA clearance of the Triathlon Total Knee system was also secured in mid-2015, however the company is planning a limited KOL launch in '16 followed by a full commercial launch in '17. The broader acceptance of Mako, in our view, is still contingent on demonstrated benefits to hospital efficiencies. CJR not a concern for SYK. SYK's views on CJR are very much in-line with feedback we recently gathered from consultants and physicians - that the program will not result in incremental implant pricing pressure but instead more focus will be on controlling postacute care costs (see Jan 26 publication). Conversely, the program may provide a growing service opportunity where SYK currently offers various solutions geared toward helping hospitals better run their orthopedic practices. Valuation/Risks Our $100 target is 18x 2016 EPS, at the high end of peers. Risks include pricing pressure, volume growth, and competition. Financial Summary HOLD Price target $ Price $96.02 Book Value (MM): 8,511.0 Book Value/Share: Net Debt (MM): ($826.0) Long-Term Debt (MM): 3,253.0 Cash & ST Invest. (MM): 4,079.0 Market Data 52 Week Range: $ $86.68 Total Entprs. Value (MM): $35,949.7 Market Cap. (MM): $36,775.7 Insider Ownership: 14.2% Institutional Ownership: 66.5% Shares Out. (MM): Float (MM): Avg. Daily Vol.: 1,594,067 Raj Denhoy * Equity Analyst (212) rdenhoy@jefferies.com Anthony Petrone, CFA * Equity Analyst (212) apetrone@jefferies.com Christian Moore * Equity Associate (212) cmoore1@jefferies.com * Jefferies LLC EQUITY RESEARCH AMERICAS USD Prev. 2014A Prev. 2015A Prev. 2016E Prev. 2017E Rev. (MM) -- 9, , , , , , ,907.0 EPS Mar Jun Sep Dec FY Dec EPS exclude amortization beginning in 2014E Price Performance JAN-15 MAY-15 SEP-15 JAN-16 Jefferies does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see analyst certifications, important disclosure information, and information regarding the status of non-us analysts on pages 5 to 9 of this report.
2 Initial 2016 guidance a balance of strong sales and reinvestment. Initial 2016 guidance calls for +5-6% cc growth and $5.50-$ EPS was generally ahead of expectations at the upper-end of the range (Street 5.0%/$5.58 vs. JEF 4.8%/$5.55). Our revised 2016 estimates settle roughly at the midpoint of guidance (new $10.4bn/$5.60; prior $10.4bn/$5.55). The company is planning on another year of reinvestment, with the benefits of the medtech tax moratorium being put back in. 50bp of margin expansion are expected on the GM line (where the medtech tax was being realized) but OM expansion is also just 50bp as R&D spending picks up the slack. Cash use still a question. While guidance is likely to be viewed favorably, questions remain around SYK s capital deployment plan given the growing cash pile (ended year with $4.1bn inclusive of $1.8bn of repatriated cash). On the M&A front, the company continues to reiterate that acquisitions are the preferred area of spending but the pace of deals slowed in 2015 (2 deals closed versus 4 in the prior year). Since being first reported by Financial Times, Bloomberg and others almost two years ago, speculation about a bid for Smith & Nephew (SN/LN, Hold) persists however, while a deal seems in line with comments out of the company that a new vertical is not a direction it s heading in any time soon, we remain skeptical. On the buy-back front, the company has $1.9bn remaining under its existing authorization with recent history suggesting that the company will keep up the pace of repurchases should deals remain elusive (7.5mn shares were repurchased at an average price of $94.67 in 2015). Chart 1: SYK Income Statement Stryker Corporation Income Statement FYE Dec 31 $ in millions, except earnings per share 2013 A 1Q14 A 2Q14 A 3Q14 A 4Q14 A 2014 A 1Q15 A 2Q15 A 3Q15 A 4Q15 A 2015 A 1Q16 E 2Q16 E 3Q16 E 4Q16 E 2016 E 2017 E Net Sales $9,021 $2,305 $2,363 $2,389 $2,618 $9,675 $2,379 $2,432 $2,420 $2,715 $9,946 $2,468 $2,532 $2,537 $2,852 $10,389 $10,907 Y/Y % 4.2% 5.2% 6.8% 11.1% 6.1% 7.2% 3.2% 2.9% 1.3% 3.7% 2.8% 3.7% 4.1% 4.8% 5.0% 4.5% 5.0% Y/Y constant currency 5.8% 6.4% 6.9% 11.3% 8.6% 8.3% 7.4% 6.9% 5.9% 6.8% 6.8% 5.0% 5.4% 5.9% 5.6% 5.5% 5.0% Cost of Goods Sold $2,931 $770 $799 $813 $888 $3,270 $818 $820 $800 $892 $3,330 $837 $846 $832 $918 $3,433 $3,578 Gross Profit $6,091 $1,535 $1,564 $1,576 $1,730 $6,405 $1,561 $1,612 $1,620 $1,823 $6,616 $1,631 $1,687 $1,705 $1,934 $6,956 $7,330 Gross Margin 67.5% 66.6% 66.2% 66.0% 66.1% 66.2% 65.6% 66.3% 66.9% 67.1% 66.5% 66.1% 66.6% 67.2% 67.8% 67.0% 67.2% Operating Expenses SG&A $3,284 $829 $841 $851 $856 $3,377 $854 $879 $862 $915 $3,510 $893 $907 $898 $950 $3,648 $3,807 % of Sales 36.4% 36.0% 35.6% 35.6% 32.7% 34.9% 35.9% 36.1% 35.6% 33.7% 35.3% 36.2% 35.8% 35.4% 33.3% 35.1% 34.9% Research and Development $536 $150 $158 $153 $153 $614 $152 $154 $155 $164 $625 $165 $165 $165 $171 $666 $677 % of Sales 5.9% 6.5% 6.7% 6.4% 5.8% 6.3% 6.4% 6.3% 6.4% 6.0% 6.3% 6.7% 6.5% 6.5% 6.0% 6.4% 6.2% Amortization $138 $45 $47 $50 $46 $188 $49 $49 $54 $58 $210 $50 $50 $50 $50 $200 $194 % of Sales 1.5% 1.9% 2.0% 2.1% 1.8% 1.9% 2.1% 2.0% 2.2% 2.1% 2.1% 2.0% 2.0% 2.0% 1.8% 1.9% 1.8% Total Operating Expenses Ex Amort $3,958 $979 $999 $1,004 $1,009 $3,991 $1,006 $1,033 $1,017 $1,079 $4,135 $1,059 $1,071 $1,063 $1,121 $4,314 $4,484 % of Sales 43.9% 42.5% 42.3% 42.0% 38.5% 41.2% 42.3% 42.5% 42.0% 39.7% 41.6% 42.9% 42.3% 41.9% 39.3% 41.5% 41.1% Operating Income ex Amort $2,133 $556 $565 $572 $721 $2,414 $555 $579 $603 $744 $2,481 $573 $615 $642 $813 $2,643 $2,846 Operating Margin 23.6% 24.1% 23.9% 23.9% 27.5% 25.0% 23.3% 23.8% 24.9% 27.4% 24.9% 23.2% 24.3% 25.3% 28.5% 25.4% 26.1% Interest & other income/(expense) ($55) ($24) ($30) ($25) ($22) ($101) ($29) ($28) ($33) ($36) ($126) ($28) ($27) ($30) ($32) ($117) ($112) Pre-Tax Income $2,078 $532 $535 $547 $699 $2,314 $526 $551 $570 $708 $2,355 $545 $588 $612 $781 $2,526 $2,734 Pre-Tax Margin 23.0% 23.1% 22.6% 22.9% 26.7% 23.9% 22.1% 22.7% 23.6% 26.1% 23.7% 22.1% 23.2% 24.1% 27.4% 24.3% 25.1% Income Taxes $463 $128 $120 $108 $147 $503 $102 $93 $94 $118 $406 $94 $101 $105 $134 $434 $470 Effective Tax Rate 22.3% 24.0% 22.4% 18.2% 21.0% 21.7% 19.4% 16.8% 16.4% 16.6% 17.2% 17.2% 17.2% 17.2% 17.2% 17.2% 17.2% Net Income (incl. min interest) $1,616 $404 $415 $439 $552 $1,811 $424 $458 $476 $590 $1,949 $451 $487 $507 $647 $2,091 $2,263 Net Income Margin 17.9% 17.5% 17.6% 18.4% 21.1% 18.7% 17.8% 18.8% 19.7% 21.7% 19.6% 18.3% 19.2% 20.0% 22.7% 20.1% 20.8% Diluted EPS - ex-amortization $4.49 $1.06 $1.08 $1.15 $1.44 $4.73 $1.11 $1.20 $1.25 $1.56 $5.12 $1.20 $1.30 $1.36 $1.75 $5.60 $ % 4.6% 10.9% 9.0% 8.2% 8.2% 8.3% 8.2% 8.7% 11.9% 9.5% 10.0% Diluted Shares Outstanding Source: Jefferies, company data page 2 of 9
3 Chart 2: SYK Revenue Model Stryker Corporation Revenue Model FYE Dec 31 $ in millions Reconstructive Knee Hips 2013 A 2014A 1Q15A 2Q15A 3Q15A 4Q15A 2015A 1Q16E 2Q16E 3Q16E 4Q16E 2016E 2017E US , ,064 1,096 International Total 1,370 1, , ,468 1,512 US International Total 1,273 1, , ,297 1,345 Trauma & Extremities US International Total 1,116 1, , ,380 1,485 Other Total Total Reconstructive $3,978 $4,153 $1,023 $1,035 $1,019 $1,145 $4,223 $1,058 $1,082 $1,072 $1,208 $4,420 $4,624 Spine US International Total $ Neurotechnology US International Total 910 1, $289 1, ,136 1,250 Total Neurotechnology and Spine $1,657 $1,741 $429 $458 $458 $483 $1,828 $452 $470 $475 $501 $1,898 $2,008 MedSurg Instruments 1,270 1, , ,539 1,616 Endoscopy 1,194 1, , ,445 1,517 Medical Sustainability Total MedSurg $3,385 $3,781 $927 $939 $943 $1,087 $3,895 $958 $980 $990 $1,143 $4,071 $4,275 Stryker Worldwide Total Sales $9,020 $9,675 $2,379 $2,432 $2,420 $2,715 $9,946 $2,468 $2,532 $2,537 $2,852 $10,389 $10,907 Currency ($140) ($93) ($97) ($95) ($110) ($82) ($384) ($30) ($30) ($25) ($15) ($100) Acquisitions OtisMed Mutoh/Synergystics Ascent Total acquisitions $68 $227 $42 $25 $15 $10 $92 $3 $3 $0 Source: Jefferies, company data page 3 of 9
4 Chart 3: SYK Revenue Model cont. Growth Rate Drivers Stryker Corporation Revenue Model FYE Dec 31 $ in millions 2013 A 2014A 1Q15A 2Q15A 3Q15A 4Q15A 2015A 1Q16E 2Q16E 3Q16E 4Q16E 2016E 2017E Reconstructive Knee US 3% 4% 2% 3% 5% 9% 5% 8% 6% 5% 5% 6% 3% International -3% -3% -8% -9% -15% -6% -10% -2% 1% 3% 4% 1% 3% Total 1% 2% -1% -1% -1% 5% 0% 5% 4% 4% 5% 5% 3% Hips US 7% 6% 7% 6% 6% 5% 6% 5% 4% 4% 4% 4% 4% International -2% -5% -13% -12% -15% -14% -14% -9% 3% 3% 3% 0% 3% Total 3% 1% -2% -2% -3% -2% -2% 0% 4% 4% 3.7% 3% 4% Trauma & Extremeties US 18% 15% 18% 18% 15% 13% 16% 11% 10% 10% 10% 10% 9% International 7% 5% -4% -12% -13% -7% -9% -3% -2% 4% 6% 1% 5% Total 13% 10% 9% 4% 3% 4% 5% 6% 6% 8% 9% 7% 8% Total Reconstructive 4% 4% 2% 1% 0% 3% 2% 3% 4% 5% 5% 5% 5% Constant currency 7% 7% Spine US 2% -2% 2% 9% 6% 9% 7% 7% 6% 5% 4% 5% 4% International 2% 2% -6% -16% -19% -16% -14% -6% -4% 2% 2% -2% 2% Total 2% 0% 0% 1% -2% 1% 0% 3% 2% 4% 3% 3% 3% Neurotechnology 13% 15% 3% 10% 10% 10% 9% 10% 10% 10% 10% 10% 10% Cement 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 2% Extr 11% 11% 0% 12% 12% 12% 11% 0% 12% 12% 12% 11% 12% Other 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 3% Total Neurotechnology and Spine 6% 5% 2% 6% 5% 6% 5% 5% 3% 4% 4% 4% 6% Constant currency 10% 10% MedSurg Instruments 1% 12% 1% 4% 3% 4% 3% 5% 5% 5% 5% 5% 5% Endoscopy 7% 15% 3% 0% -3% 2% 1% 2% 4% 5% 5% 4% 5% Medical 3% 8% 14% 11% 3% 4% 7% 3% 5% 6% 7% 5% 6% Sustainability 4% 3% 9% 4% 0% 1% 0% 1% 1% 1% 1% 1% 1% Total MedSurg 4% 12% 5% 4% 1% 3% 3% 3% 4% 5% 5% 5% 5% Constant currency 6% 6% Stryker Worldwide Total Sales 4.2% 7.3% 3.2% 2.9% 1.3% 3.7% 2.8% 3.7% 4.1% 4.9% 5.0% 4.5% 5.0% WW Grow th ex-currency 5.8% 8.3% 7.4% 6.9% 5.9% 6.8% 6.8% 5.0% 5.4% 5.9% 5.6% 5.5% 5.0% WW Grow th ex-acquisitions 3.4% 4.7% 1.4% 1.9% 0.6% 3.3% 1.8% 3.6% 4.1% 4.9% 5.0% 4.4% 5.0% WW Grow th ex-fx & acq. 5.0% 5.8% 5.6% 5.9% 5.3% 6.4% 6.1% 4.9% 5.4% 5.9% 5.6% 5.4% 5.0% OUS Grow th ex-currency 6% 13% -88% -89% -87% -12% -8% Source: Jefferies, company data page 4 of 9
5 Company Description Stryker is the #3 player in the worldwide orthopedics market. Its sales are split 60/40 between reconstructive implants and Medical Surgery equipment (MedSurg). Analyst Certification: I, Raj Denhoy, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) and subject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report. I, Anthony Petrone, CFA, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) and subject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report. I, Christian Moore, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) and subject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report. As is the case with all Jefferies employees, the analyst(s) responsible for the coverage of the financial instruments discussed in this report receives compensation based in part on the overall performance of the firm, including investment banking income. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Aside from certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgement. Explanation of Jefferies Ratings Buy - Describes securities that we expect to provide a total return (price appreciation plus yield) of 15% or more within a 12-month period. Hold - Describes securities that we expect to provide a total return (price appreciation plus yield) of plus 15% or minus 10% within a 12-month period. Underperform - Describes securities that we expect to provide a total return (price appreciation plus yield) of minus 10% or less within a 12-month period. The expected total return (price appreciation plus yield) for Buy rated securities with an average security price consistently below $10 is 20% or more within a 12-month period as these companies are typically more volatile than the overall stock market. For Hold rated securities with an average security price consistently below $10, the expected total return (price appreciation plus yield) is plus or minus 20% within a 12-month period. For Underperform rated securities with an average security price consistently below $10, the expected total return (price appreciation plus yield) is minus 20% or less within a 12-month period. NR - The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/ or Jefferies policies. CS - Coverage Suspended. Jefferies has suspended coverage of this company. NC - Not covered. Jefferies does not cover this company. Restricted - Describes issuers where, in conjunction with Jefferies engagement in certain transactions, company policy or applicable securities regulations prohibit certain types of communications, including investment recommendations. Monitor - Describes securities whose company fundamentals and financials are being monitored, and for which no financial projections or opinions on the investment merits of the company are provided. Valuation Methodology Jefferies' methodology for assigning ratings may include the following: market capitalization, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months. Jefferies Franchise Picks Jefferies Franchise Picks include stock selections from among the best stock ideas from our equity analysts over a 12 month period. Stock selection is based on fundamental analysis and may take into account other factors such as analyst conviction, differentiated analysis, a favorable risk/reward ratio and investment themes that Jefferies analysts are recommending. Jefferies Franchise Picks will include only Buy rated stocks and the number can vary depending on analyst recommendations for inclusion. Stocks will be added as new opportunities arise and removed when the reason for inclusion changes, the stock has met its desired return, if it is no longer rated Buy and/or if it triggers a stop loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a 15% stop loss, and the remainder will have a 20% stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not sector based, but we may note where we believe a Pick falls within an investment style such as growth or value. Risks which may impede the achievement of our Price Target This report was prepared for general circulation and does not provide investment recommendations specific to individual investors. As such, the financial instruments discussed in this report may not be suitable for all investors and investors must make their own investment decisions based upon their specific investment objectives and financial situation utilizing their own financial advisors as they deem necessary. Past performance of page 5 of 9
6 the financial instruments recommended in this report should not be taken as an indication or guarantee of future results. The price, value of, and income from, any of the financial instruments mentioned in this report can rise as well as fall and may be affected by changes in economic, financial and political factors. If a financial instrument is denominated in a currency other than the investor's home currency, a change in exchange rates may adversely affect the price of, value of, or income derived from the financial instrument described in this report. In addition, investors in securities such as ADRs, whose values are affected by the currency of the underlying security, effectively assume currency risk. Other Companies Mentioned in This Report Smith & Nephew (SN/ LN: p1,142.00, HOLD) page 6 of 9
7 Distribution of Ratings IB Serv./Past 12 Mos. Rating Count Percent Count Percent BUY % % HOLD % % UNDERPERFORM % % page 7 of 9
8 Other Important Disclosures Jefferies Equity Research refers to research reports produced by analysts employed by one of the following Jefferies Group LLC ( Jefferies ) group companies: United States: Jefferies LLC which is an SEC registered firm and a member of FINRA. United Kingdom: Jefferies International Limited, which is authorized and regulated by the Financial Conduct Authority; registered in England and Wales No ; registered office: Vintners Place, 68 Upper Thames Street, London EC4V 3BJ; telephone +44 (0) ; facsimile +44 (0) Hong Kong: Jefferies Hong Kong Limited, which is licensed by the Securities and Futures Commission of Hong Kong with CE number ATS546; located at Suite 2201, 22nd Floor, Cheung Kong Center, 2 Queen s Road Central, Hong Kong. Singapore: Jefferies Singapore Limited, which is licensed by the Monetary Authority of Singapore; located at 80 Raffles Place #15-20, UOB Plaza 2, Singapore , telephone: Japan: Jefferies (Japan) Limited, Tokyo Branch, which is a securities company registered by the Financial Services Agency of Japan and is a member of the Japan Securities Dealers Association; located at Hibiya Marine Bldg, 3F, Yuraku-cho, Chiyoda-ku, Tokyo ; telephone ; facsimile India: Jefferies India Private Limited (CIN - U74140MH2007PTC200509), which is licensed by the Securities and Exchange Board of India as a Merchant Banker (INM ), Research Analyst (INH ) and a Stock Broker with Bombay Stock Exchange Limited (INB ) and National Stock Exchange of India Limited (INB ) in the Capital Market Segment; located at 42/43, 2 North Avenue, Maker Maxity, Bandra-Kurla Complex, Bandra (East) Mumbai , India; Tel This material has been prepared by Jefferies employing appropriate expertise, and in the belief that it is fair and not misleading. The information set forth herein was obtained from sources believed to be reliable, but has not been independently verified by Jefferies. Therefore, except for any obligation under applicable rules we do not guarantee its accuracy. Additional and supporting information is available upon request. Unless prohibited by the provisions of Regulation S of the U.S. Securities Act of 1933, this material is distributed in the United States ("US"), by Jefferies LLC, a US-registered broker-dealer, which accepts responsibility for its contents in accordance with the provisions of Rule 15a-6, under the US Securities Exchange Act of Transactions by or on behalf of any US person may only be effected through Jefferies LLC. In the United Kingdom and European Economic Area this report is issued and/or approved for distribution by Jefferies International Limited and is intended for use only by persons who have, or have been assessed as having, suitable professional experience and expertise, or by persons to whom it can be otherwise lawfully distributed. Jefferies International Limited has adopted a conflicts management policy in connection with the preparation and publication of research, the details of which are available upon request in writing to the Compliance Officer. Jefferies International Limited may allow its analysts to undertake private consultancy work. Jefferies International Limited s conflicts management policy sets out the arrangements Jefferies International Limited employs to manage any potential conflicts of interest that may arise as a result of such consultancy work. For Canadian investors, this material is intended for use only by professional or institutional investors. None of the investments or investment services mentioned or described herein is available to other persons or to anyone in Canada who is not a "Designated Institution" as defined by the Securities Act (Ontario). In Singapore, Jefferies Singapore Limited is regulated by the Monetary Authority of Singapore. For investors in the Republic of Singapore, this material is provided by Jefferies Singapore Limited pursuant to Regulation 32C of the Financial Advisers Regulations. The material contained in this document is intended solely for accredited, expert or institutional investors, as defined under the Securities and Futures Act (Cap. 289 of Singapore). If there are any matters arising from, or in connection with this material, please contact Jefferies Singapore Limited, located at 80 Raffles Place #15-20, UOB Plaza 2, Singapore , telephone: In Japan this material is issued and distributed by Jefferies (Japan) Limited to institutional investors only. In Hong Kong, this report is issued and approved by Jefferies Hong Kong Limited and is intended for use only by professional investors as defined in the Hong Kong Securities and Futures Ordinance and its subsidiary legislation. In the Republic of China (Taiwan), this report should not be distributed. The research in relation to this report is conducted outside the PRC. This report does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. In India this report is made available by Jefferies India Private Limited. In Australia this information is issued solely by Jefferies International Limited and is directed solely at wholesale clients within the meaning of the Corporations Act 2001 of Australia (the "Act") in connection with their consideration of any investment or investment service that is the subject of this document. Any offer or issue that is the subject of this document does not require, and this document is not, a disclosure document or product disclosure statement within the meaning of the Act. Jefferies International Limited is authorised and regulated by the Financial Conduct Authority under the laws of the United Kingdom, which differ from Australian laws. Jefferies International Limited has obtained relief under Australian Securities and Investments Commission Class Order 03/1099, which conditionally exempts it from holding an Australian financial services licence under the Act in respect of the provision of certain financial services to wholesale clients. Recipients of this document in any other jurisdictions should inform themselves about and observe any applicable legal requirements in relation to the receipt of this document. This report is not an offer or solicitation of an offer to buy or sell any security or derivative instrument, or to make any investment. Any opinion or estimate constitutes the preparer's best judgment as of the date of preparation, and is subject to change without notice. Jefferies assumes no obligation to maintain or update this report based on subsequent information and events. Jefferies, its associates or affiliates, and its respective officers, directors, and employees may have long or short positions in, or may buy or sell any of the securities, derivative instruments or other investments mentioned or described herein, either as agent or as principal for their own account. Upon request Jefferies may provide specialized research products or services to certain customers focusing on the prospects for individual covered stocks as compared to other covered stocks over varying time horizons or under differing market conditions. While the views expressed in these situations may not always be directionally consistent with the long-term views expressed in the analyst's published research, the analyst has a reasonable basis and any inconsistencies can be reasonably explained. This material does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of the investments referred to herein and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments. This report has been prepared independently of any issuer of securities mentioned herein and not in connection with any proposed offering of securities or as agent of any issuer of securities. None of Jefferies, any of its affiliates or its research analysts has any authority whatsoever to make any representations or warranty on behalf of the issuer(s). page 8 of 9
9 Jefferies policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer prior to the publication of a research report containing such rating, recommendation or investment thesis. Any comments or statements made herein are those of the author(s) and may differ from the views of Jefferies. This report may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor s. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information, including ratings, and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase, hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice. Jefferies research reports are disseminated and available primarily electronically, and, in some cases, in printed form. Electronic research is simultaneously available to all clients. This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of Jefferies. Neither Jefferies nor any officer nor employee of Jefferies accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this report or its contents. For Important Disclosure information, please visit our website at or call JEFFERIES 2016 Jefferies Group LLC page 9 of 9
Health Care Facilities
Page 1 of 5 INDUSTRY NOTE USA Healthcare Health Care Facilities July 21, 2014 Health Care Facilities Hospital Survey: Inpatient Volumes Were Positive; Expect More Doc Outsourcing Key Takeaway We conducted
More informationPrecision Equipment Obstacles for EUVL
INDUSTRY NOTE Japan Industrials Obstacles for EUVL Key Takeaway It seems that developing the mirror is one of the major obstacles in realizing EUVL lithography. We also summarize the other obstacles (both
More informationBiotechnology BIIB/Bioverativ: Filings Reveal Incremental New Info On Hemophilia Spinoff
INDUSTRY NOTE USA Healthcare BIIB/Bioverativ: Filings Reveal Incremental New Info On Hemophilia Spinoff Key Takeaway This afternoon the Form 10 for BIIB s proposed hemophilia spinoff Bioverativ was issued,
More informationMicron Tech. (MU) EQUITY RESEARCH AMERICAS. Moore Stress: Expect DRAM Prices to Continue to Increase. BUY Price target $10.00 Price $9.
USA Technology Semiconductors Micron Tech. (MU) Moore Stress: Expect DRAM Prices to Continue to Increase Key Takeaway DRAM spot prices have spiked up 106% and contract prices increased by 30% from their
More informationMajor Bulk Commodities: Trends and Outlook
Major Bulk Commodities: Trends and Outlook June 19, 2013 Christopher LaFemina European Metals and Mining Equity Research US: 212 336 7304 UK: +44 (0)207 029 8131 clafemina@jefferies.com Jefferies LLC Seaborne
More informationAmerican Tower (AMT) EQUITY RESEARCH AMERICAS. Strong Execution Continues. BUY Price target $ Price $90.01 COMPANY NOTE.
COMPANY NOTE USA Telecommunications Telecom Services American Tower (AMT) Strong Execution Continues Key Takeaway AMT beat on all key financial metrics, with acquisitions and strong organic growth expected
More informationFufeng Group Limited (546 HK) Second Price Increase in Two Months
COMPANY NOTE China Industrials Chemicals Fufeng Group Limited (546 HK) Second Price Increase in Two Months Key Takeaway Fufeng has adjusted its MSG prices again, the second time since late April. Excluding
More informationFY3/17 JEF forecast. FY3/17 company forecast. Implied progression
INDUSTRY NOTE Japan Financials Financials Today at the Races Key Takeaway Today's runners: Nikkei previewed Q1 FY3/17 banks earnings; Janus reported 2Q16 results slight operating miss with positive flows;
More informationVerizon Communications (VZ) ARPA Headwinds Likely to Persist
COMPANY NOTE USA Telecommunications Telecom Services Verizon Communications (VZ) ARPA Headwinds Likely to Persist Key Takeaway Similar to 3Q, better profitability in both Wireless and Wireline drove a
More informationPublic Service Ent. (PEG) Another Bad Bonus
COMPANY NOTE USA Energy Electric Utilities Public Service Ent. (PEG) Another Bad Bonus Key Takeaway PEG hosted its investor conference and affirmed 2016 ongoing EPS guidance of $2.80-$3.00 and as a result
More informationComputer Services & IT Consulting JPM Card Volume Growth Accelerates
INDUSTRY NOTE USA Technology JPM Card Volume Growth Accelerates Key Takeaway Earlier, JPM (largest V/MA credit card issuer) reported 2Q16 results. US credit card volume growth accelerated 30 bps to 8.2%
More informationTullett Prebon (LSE: TLPR LN)
December 1, 2008 Financial Services Market Structure & Trading United Kingdom Company Update Rating: Price: Price Target: Bloomberg: BUY 150p 260p LSE: TLPR LN Market Data 52-Week Range: 540p-125p Total
More informationAmerican Electric Power (AEP)
COMPANY NOTE USA Energy Electric Utilities American Electric Power (AEP) Strong 3Q15 and Increased 2015 Guidance Key Takeaway AEP reported 3Q15 EPS of $1.06, which beat Street expectations of $1.00 and
More informationKinross Gold Corp. (KGC)
COMPANY NOTE USA Natural Resources Metals & Mining Kinross Gold Corp. (KGC) Good Operational Performance, Capex Lowered Key Takeaway Kinross reported adjusted 3Q EPS of $0.10, ahead of our and street s
More informationLattice Semiconductor (LSCC) Moore Stress Beneficiary - Takeaways From Management Meetings
USA Technology Semiconductors Lattice Semiconductor (LSCC) Moore Stress Beneficiary - Takeaways From Management Meetings Key Takeaway After hosting investor meetings with CFO Joe Bedewi and VP Ops. Doug
More informationHEG (HEG IN) EQUITY RESEARCH INDIA. Strong Quarter; Raising PT. BUY Price target INR5, (from INR4,400.00) Price INR4,343.
COMPANY NOTE India Natural Resources Materials (Steel) HEG (HEG IN) Strong Quarter; Raising PT Key Takeaway HEG reported strong quarter driven by higher realisation of US$14,333/t (vs US $12,500/t JEFe).
More informationConsumer. Nevada Numbers - Average Nevada Income Statements Back To 1991
January 30, 2009 Consumer Casinos & Gaming Consumer Nevada Numbers - Average Nevada Income Statements Back To 1991 Investment Summary The enclosed note gives readers a financial snapshot of the typical
More informationTCL Communication (2618 HK)
COMPANY NOTE HKG Technology Comm. Equipment TCL Communication (2618 HK) Look Forward to Smartphone Growth Key Takeaway TCL Comm reported Q1 earnings materially below our/consensus expectations due to pricing
More informationAveXis (AVXS) EQUITY RESEARCH AMERICAS. Survey Says...Parents Would Be Interested In AVXS-101 Pivotal Trial. BUY Price target $50.00 Price $41.
COMPANY NOTE USA Healthcare Biotechnology AveXis (AVXS) Survey Says...Parents Would Be Interested In AVXS-101 Pivotal Trial Key Takeaway Since there are investor questions surrounding AVXS' ability to
More informationGalapagos (GLPG NA) EQUITY RESEARCH EUROPE. Cash Burn Aim Unchanged at 1Q; Pipeline On-track; Call to Focus on CF Specifics
Netherlands Healthcare Biotechnology Galapagos (GLPG NA) Cash Burn Aim Unchanged at 1Q; Pipeline On-track; Call to Focus on CF Specifics Key Takeaway 1Q cash burn is as expected and 2018 outlook reiterated
More informationStryker Corp. Post-4Q15 Thoughts
EQUITY RESEARCH QUARTERLY UPDATE January 27, 2016 Stock Rating: PERFORM 12-18 mo. Price Target $104.00 SYK - NYSE $96.02 3-5 Yr. EPS Gr. Rate 9% 52-Wk Range $105.34-$86.68 Shares Outstanding 378.4M Float
More informationStrides Arcolab (STR IN)
COMPANY NOTE India Healthcare Pharmaceuticals Strides Arcolab () 1Q18: Weak quarter; Expect recovery ahead Key Takeaway STR reported weak 1Q18 as approval delays, mix and operating leverage drove 700bps
More informationAmerica's Car-Mart (CRMT)
COMPANY NOTE Target Estimate Change USA Financials Consumer Finance February 20, 2014 America's Car-Mart (CRMT) CRMT 3Q14: Competitive Intensity Leads to Higher Credit Costs Key Takeaway CRMT missed consensus
More informationMaterials (Steel) Scrap Preview: May Momentum Persists on Strong Exports; Up +$25-30/t
INDUSTRY NOTE USA Industrials Scrap Preview: May Momentum Persists on Strong Exports; Up +$25-30/t Key Takeaway Recyclers expect May scrap prices to move up +$25-30/t on a) strong export demand/pricing
More informationMaterials (Steel) China s Silicon Price Inflects; Western US/EU Continue Gains
INDUSTRY NOTE USA Industrials China s Silicon Price Inflects; Western US/EU Continue Gains Key Takeaway China s Si metal prices appear to have stabilized and inflected over the past week, an encouraging
More informationFLASH Mega Manunggal Company Update 2 April 2018
FLASH Mega Manunggal FLASH Mega Manunggal Mandiri Sekuritas Analyst Audrey Hanzdima +6221 5296 9434 audrey.hanzdima@mandirisek.co.id Adrian Joezer +6221 5296 9415 adrian.joezer@mandirisek.co.id Sector:
More informationYamaha Motor (7272 JP)
COMPANY NOTE JPN Industrials Autos & Auto Parts Yamaha Motor (7272 JP) Initiate at Hold: Concern over Declining Competitiveness in Emerging Countries Key Takeaway Investment sentiment for Yamaha would
More informationSanDisk Corporation (SNDK) Moore Stress in Play - Expect Gross Margin Upside, Raise PT to $59
COMPANY NOTE USA Technology Semiconductors SanDisk Corporation () Moore Stress in Play - Expect Gross Margin Upside, Raise PT to $59 Key Takeaway We continue to believe Moore Stress is driving industry
More informationSemiconductors Weekly: Semis Flat on 6% Cuts - Moore Stress Beneficiaries Outperforming
INDUSTRY NOTE USA Weekly: Semis Flat on 6% Cuts - Moore Stress Beneficiaries Outperforming Key Takeaway Data from 37 semiconductor earnings reports shows that at the median, semis lowered 4Q revenue expectations
More information26.0x 19.8x 17.5x 16.5x
COMPANY NOTE USA Technology Software Citrix (CTXS) Synergy User Conference and Analyst Day Key Takeaway We attended CTXS' annual user conference, Synergy, and Analyst Day in Las Vegas. Although there was
More informationTrumponomics, The Honma Accord & JGB Bondfire
May 2017 Trumponomics, The Honma Accord & JGB Bondfire David Zervos Chief Market Strategist dzervos@jefferies.com +1 212 323 7586 The Trump policy equation Summarizing The Trump Policy Effect On Expected
More informationFerroglobe (GSM) EQUITY RESEARCH AMERICAS
COMPANY NOTE USA Industrials Materials (Steel) Ferroglobe (GSM) US Levies 4-135% Preliminary Si Metal Antidumping Duties; Reiterate Buy Key Takeaway The imposition of US Si metal import duties of 4-135%
More informationTechnology EQUITY RESEARCH GLOBAL. PC Hardware: More Headwinds Ahead INDUSTRY NOTE. Hong Kong Technology 11 April 2013
INDUSTRY NOTE Hong Kong PC Hardware: More Headwinds Ahead Key Takeaway PC market continues to deteriorate with unlikely recovery in C2Q13 before Intel launching Haswell. For Asian PC vendors, we see additional
More informationResearch in Motion (RIMM)
COMPANY NOTE USA Technology Telecom Equipment/Wireless Research in Motion (RIMM) Limited Patent Value; Cut Target to Salvage Value of $21 as We Wait for QNX Key Takeaway In consultation with industry experts,
More informationBCD Semiconductor (BCDS)
COMPANY NOTE USA Technology Semiconductors BCD Semiconductor (BCDS) Moore Stress Beneficiary Taking Share - Buy Key Takeaway Q3 EPS beat highlights another quarter of consistent execution and share gains
More informationDry Bulk Sector Panel
Capital Link Forum March 12, 2018 Maritime Shipping Dry Bulk Sector Panel Randy Giveans Maritime Shipping Group Head Equity Analyst rgiveans@jefferies.com 713.651.3829 Jefferies LLC Disclaimer: Important
More informationVertex (VRTX) EQUITY RESEARCH AMERICAS
COMPANY NOTE USA Healthcare Biotechnology Vertex (VRTX) 3Q16: Next-Gens Good Enough To Proceed, A Meaningful Step Key Takeaway Numbers in line, but 3Q highlighted by both next-gen correctors, despite imperfect
More informationMetals & Mining Incremental Positives for Iron Ore
INDUSTRY NOTE Global Natural Resources Incremental Positives for Iron Ore Key Takeaway A likely shift in Chinese real estate policy to address under-supply of affordable housing in major cities should
More informationSoftware IBM 2Q15: Difficult Software Read Across Due to Secular Challenges
INDUSTRY NOTE USA Technology IBM 2Q15: Difficult Read Across Due to Secular Challenges Key Takeaway As the third largest vendor in the world, we consider IBM s results a gauge on the industry, though we
More informationKWG. Seeking balance between scale and profitability. March 27, 2018 Equity Research. Stock code: 1813.HK Rating: HOLD Price target (HK$) 12.
Equity Research Seeking balance between scale and profitability Downgrade to HOLD and revise down TP to HK$12.50: 2017 result missed our estimation; core net profit dropped by 19% YoY, expansion execution
More informationCR Lands. Winner of next 5 years, BUY. March 21, 2018 Equity Research. Stock code: 1109.HK Rating: BUY Price target (HK$) 34.74
Equity Research Winner of next 5 years, BUY 2017 result: slow growth, but high profitability Revenue slightly improved by 8.5% YoY to HKD 118.5 bn. Thanks to GPM growing by 6.5 pts to 40%, gross profit
More informationEarnings sustainability and asset quality remain under pressure
Bank of Chongqing (1963 HK; TP H KD6.85; H OLD) Bank of Chongqing (1963 HK) Equity Research Earnings sustainability and asset quality remain under pressure Huatai Research 30 October 2017 Equity China
More informationImportant Notices Disclaimer: This document has been prepared by National Australia Bank Limited ABN 12 004 044 937 AFSL 230686 ( NAB ). Any advice contained in this document has been prepared without
More informationE-FIT trial results indicate no clinical improvement
NEXSTIM OYJ Medical Technology 3 September 2018 11:44 BST FLASH NOTE Nexstim OYJ (NXTMH-FI) E-FIT trial results indicate no clinical improvement OUTPERFORM Price target 1.23 Price 0.23 KEY TAKEAWAY Today,
More informationManulife Financial Corp.
I N S T I T U T I O N A L E Q U I T Y R E S E A R C H Robert Sedran, CFA 1 (416) 594-7874 Robert.Sedran@cibc.com Koki Akala, CFA 1 (416) 956-3723 Koki.Akala@cibc.com Maurissa Bell, CPA, CA 1 (416) 594-7283
More informationMGIC Investment Corporation
Upsi de 25.1% 09-Mar-2015, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A Equity Research October 15, 2015 Mark Palmer (212) 588-6582 mpalmer@btig.com Giuliano
More informationUS Equity Strategy EQUITY STRATEGY AMERICAS. JEF's SMID-Cap Themes: 8 is enough, go with the Momentum and 7 other themes STRATEGY NOTE
STRATEGY NOTE A Equity Strategy Equity Strategy JEF's SMID-Cap Themes: 8 is enough, go with the Momentum and 7 other themes Key Takeaway We thought 7 themes were enough but decided to add an 8th and that
More informationNestlé India Outlook Hazy; Valuations Prohibitive
Nestlé India Outlook Hazy; Valuations Prohibitive Nestlé India s net sales, EBITDA and net profit surged by 35% yoy, 67% yoy & 116% yoy to Rs23.5bn, Rs4.5bn & Rs2.7bn, respectively in 3QCY16. This growth
More informationVIX to Fall; Stocks to Rise; Small to Outperform
RBC Capital Markets, LLC October 14, 2014 VIX to Fall; Stocks to Rise; Small to Outperform Market Delivers Above-Average Returns Following Volatility Spikes Investor concerns regarding global growth have
More informationTCL Communication (2618 HK) Painful transition period. Buy (Maintain) Target Price HK$2.33 Up/downside +28.5% Current price HK$1.
Securities Analysis (Equity) TCL Communication (218 HK) Painful transition period 1H12 profit warning. TCL Com announced profit warning on 15 Jul and expected to record a significant drop in 2Q12 net profit
More informationUS Rates Outlook: The Fed s Third Mandate
US Rates Outlook: The Fed s Third Mandate April 2016 Gennadiy Goldberg US Rates Strategist gennadiy.goldberg@tdsecurities.com 1 (212) 827-7180 Lopsided employment picture rapidly improving 2 Wage inflation:
More informationDarden Restaurants, Inc.
Darden Restaurants, Inc. DRI: Reports Solid Performance; Expectations Were Pretty High Despite Evidence Segment Is Slowing Our View: We reiterate our OW rating following shares coming under pressure because
More information3Q 30 SEPTEMBER 2018 MFS U.K. EQUITY (USD)
3Q 30 SEPTEMBER MFS U.K. EQUITY (USD) INVESTMENT OVERVIEW TEAM Name (Years of industry experience) Title Christopher Jennings, CFA (20 yrs.) Portfolio Manager David Shindler (17 yrs.) Portfolio Manager
More informationO'Reilly Automotive, Inc. Quick Read: Weather Likely Weighed Upon Sales a Bit
EQUITY RESEARCH QUARTERLY UPDATE July 27, 2016 Stock Rating: OUTPERFORM 12-18 mo. Price Target $300.00 ORLY - NASDAQ $277.51 3-5 Yr. EPS Gr. Rate 18% 52-Wk Range $284.66-$225.12 Shares Outstanding 99.4M
More information3Q 30 SEPTEMBER 2018 MFS EUROPEAN EQUITY EX U.K. (USD)
3Q 30 SEPTEMBER 2018 MFS EUROPEAN EQUITY EX U.K. (USD) INVESTMENT OVERVIEW TEAM Name (Years of industry experience) Title Matthew Barrett, ASIP (22 yrs.) Portfolio Manager Gabrielle Gourgey (23 yrs.) Institutional
More informationCity of London Investment Group*
For FCA purposes this is a Marketing Communication City of London Investment Group* CLIG LN Tough 1H trading update Financials What s new. CLIG s 1H trading update released this morning reveals details
More informationIndia Equity Strategy What Next? No. 5 VDIS
STRATEGY NOTE Equity Strategy Equity Strategy What Next? No. 5 VDIS Key Takeaway Repatriation of black money stashed abroad has been a pet theme of the BJP. The environment is probably quite conducive
More informationSizing Up the Online Lending Market: Key Trends & Themes
Sizing Up the Online Lending Market: Key Trends & Themes John Hecht jhecht@jefferies.com 415.229.1569 AGENDA Landscape of Specialty Finance Marketplace / Technology Enabled Lending Market Size, Trends
More informationCMP* (Rs) 208 Upside/ (Downside) (%) 18. Market Cap. (Rs bn) Free Float (%) 65.6 Shares O/S (mn) 630
1QFY18 Result Update July 28,2017 CMP* (Rs) 208 Bloomberg Ticker CROMPTON IN Market Cap. (Rs bn) 130.6 Free Float (%) 65.6 Shares O/S (mn) 630 Channel De-stocking Impairs Top-line; Recovery Ahead Crompton
More informationBUY. Suprajit Engineering (SEL) Automobiles
Suprajit Engineering (SEL) Automobiles Strong performance. Suprajit Engineering reported a consolidated net profit of `210 mn in 3QFY16, which was 2% higher than our estimates. Phoenix Lamps was consolidated
More informationCMP* (Rs) 417 Upside/ (Downside) (%) 46 Bloomberg Ticker. SUNP IN Market Cap. (Rs bn) 1,001 Free Float (%) 46 Shares O/S (mn) 2399
Company Update January 22, 2019 Market Cap. (Rs bn) 1,001 Free Float (%) 46 Shares O/S (mn) 2399 Multiple Growth Drivers in Place despite Near-term Headwinds Industries (SUNP) has released an investor
More informationCMP* (Rs) 242 Upside/ (Downside) (%) 2. Market Cap. (Rs bn) 157 Free Float (%) 65.6 Shares O/S (mn) 630
4QFY17 Result Update June 02,2017 Market Cap. (Rs bn) 157 Free Float (%) 65.6 Shares O/S (mn) 630 Decent Performance to Continue; Maintain Crompton Greaves Consumer Electricals (CGCEL) has delivered a
More informationKBRO KAUFMAN BROS. MORNING EXCHANGE. July 10, In Today's Morning Exchange:
In Today's Morning Exchange: Initiation of Coverage American Superconductor Corp. Earnings Previews Google Company/Industry Comments IT Services & Software CHINA WIND TURBINE MARKET AT 10GW NOW THOUGHTS
More informationManappuram Finance (MGFL IN) Healthy operating performance
INSTITUTIONAL EQUITY RESEARCH Manappuram Finance (MGFL IN) Healthy operating performance INDIA BFSI Quarterly Update Top takeaways from Q2FY19 Operating results ahead of expectations with NII/PAT at Rs
More informationKEI (KEII IN) EQUITY RESEARCH INDIA. Holistic India Play; Initiate at Buy. BUY Price target INR Price INR400.
COMPANY NOTE India Industrials Engineering & Construction KEI (KEII IN) Holistic India Play; Initiate at Buy Key Takeaway KEI Industries (KEI) is one of the top-four organised players in the Indian cable
More informationU.S. EQUITIES: VALUATION & FUNDAMENTALS
LM Market Insight: U.S. EQUITIES: VALUATION & FUNDAMENTALS DEC 2015 THIS MATERIAL IS ONLY FOR DISTRIBUTION IN THOSE COUNTRIES AND TO THOSE RECIPIENTS LISTED. PLEASE REFER TO THE DISCLOSURE INFORMATION
More informationCMP* (Rs) 840 Upside/ (Downside) (%) (2.4) Bloomberg Ticker Market Cap. (Rs bn) 379 Free Float (%) 53 Shares O/S (mn) 451.6
Event Update November 08, 2017 Market Cap. (Rs bn) 379 Free Float (%) 53 Shares O/S (mn) 451.6 USFDA Warning Letter Entails Further Downside Risk to US Biz The US FDA has issued a Warning Letter (WL) to
More informationThe Medicines Company Model Update; Busy Catalyst Calendar Ahead
EQUITY RESEARCH QUARTERLY UPDATE March 23, 2016 Stock Rating: PERFORM 12-18 mo. Price Target NA MDCO - NASDAQ $31.48 3-5 Yr. EPS Gr. Rate NA 52-Wk Range $43.79-$25.27 Shares Outstanding 68.9M Float 67.1M
More information2Q 30 JUNE 2018 MFS GLOBAL EQUITY (AUD)
2Q 30 JUNE 2018 MFS GLOBAL EQUITY (AUD) INVESTMENT OVERVIEW TEAM Name (Years of industry experience) Title Roger Morley (21 yrs.) Portfolio Manager Ryan P. McAllister, CFA (15 yrs.) Portfolio Manager Ben
More informationAutoZone, Inc. EQUITY RESEARCH QUARTERLY UPDATE OUTPERFORM. Quick Read: Sales a Bit Soft, But Results Solid. September 22, 2016
EQUITY RESEARCH QUARTERLY UPDATE September 22, 2016 Stock Rating: OUTPERFORM 12-18 mo. Price Target $900.00 AZO - NYSE $751.45 3-5 Yr. EPS Gr. Rate 14% 52-Wk Range $819.54-$681.01 Shares Outstanding 30.8M
More informationShenhua Reuters: 1088.HK, Bloomberg: 1088 HK; YCM Reuters: 1171.HK, Bloomberg: 1171 HK
20 December 20 China Coal Market Decelerating production growth Firm spot coal prices expected in 2006: China s coal production in November only grew by 3.1% Y/Y, highlighting the production disruption
More informationMIXED MESSAGES. KEY POINTS The ANZ Truckometer indexes lifted in August.
ANZ RESEARCH 11 September 18 CONTACT: Sharon Zollner Chief Economist Telephone: +6 9 357 9 Email: Sharon.Zollner@anz.com The next issue of the ANZ Truckometer is scheduled for release on 9 October 18 at
More informationCMP (Rs) 775 Upside/ (Downside) (%) (1.4) Market Cap. (Rs bn) 11.4 Free Float (%) 35.0 Shares O/S (mn) 14.7
2QFY18 Result Update November 23, 2017 Market Cap. (Rs bn) 11.4 Free Float (%) 35.0 Shares O/S (mn) 14.7 High Order Book Provides Revenue Visibility (PMPL) has delivered a healthy performance in 2QFY18.
More informationFIRST GLANCE COMMENT. Enbridge Inc. (TSX: ENB; 36.69; NYSE: ENB) Q1/07 Results Generally In Line. Sector Perform Average Risk. Impact Neutral.
125 WEEKS 17DEC04-01MAY07 Rel. S&P/TSX COMPOSITE INDEX HI-20MAY05 110.97 110.00 HI/LO DIFF -24.90% 100.00 90.00 40.00 38.00 36.00 34.00 32.00 30.00 28.00 7500 6000 4500 3000 1500 2005 D J F M A M J J A
More informationAll you need to know about the Golden Cross
All you need to know about the Golden Cross Golden Cross means market base-building to higher returns A Golden Cross is when the 50-day moving average crosses above the 200-day moving average on the S&P
More informationHOLD. Deleveraging story playing out RAMCO CEMENTS. Target Price: Rs 503. Q4 performance
RAMCO S HOLD Target Price: Rs 503 Deleveraging story playing out Ramco Cements total debt reduced by a massive Rs 5 bn to Rs 22 bn in FY16. The company generated total EBITDA of Rs 11.5 bn in FY16 and
More informationFigure 1. ANZ Heavy Traffic Index and GDP. Heavy traffic index, 3-month avg (LHS) Figure 2. ANZ Light Traffic Index and GDP
ANZ Research ANZ NZ Truckometer 1 March 19 This is not personal advice. It does not consider your objectives or circumstances. Please refer to the Important Notice. CONTACT: Sharon Zollner Chief Economist
More informationLifeVantage Corp. NasdaqCM: LFVN
LifeVantage Corp. NasdaqCM: LFVN New Products and Valuation Outweigh issues in Japan, reiterate Strong Buy LifeVantage Corp (LFVN) focuses on selling healthy living products through direct selling. They
More informationFLASH NOTE EQUITY RESEARCH. OUTPERFORM Price target 6.40 Price Elanix Biotechnologies AG (ELN-DE) Updates from webcast include financial outlook
ELANIX BIOTECHNOLOGIES AG Biotechnology 8 August 2018 09:54 BST FLASH NOTE Elanix Biotechnologies AG (ELN-DE) Updates from webcast include financial outlook OUTPERFORM Price target 6.40 Price 2.72 KEY
More informationRMBS ARREARS STATISTICS
RMBS ARREARS STATISTICS Australia (Excluding Non-Capital Market Issuance) At February 9, RMBS Performance Watch Australia at February 9, Australia Prime Standard & Poor's Rating Services Mortgage Performance
More informationCanadian Equity Strategy
INVESTMENT STRATEGY I RESEARCH Canadian Equity Strategy The U.S. Election Oct-16 RBC Dominion Securities Inc. Matthew Barasch (Chief Canadian Equity Strategist) (416) 842-7857 matt.barasch@rbccm.com This
More information2Q 30 JUNE 2018 MFS INTERNATIONAL SMALL-MID CAP EQUITY (USD)*
2Q 30 JUNE 2018 MFS INTERNATIONAL SMALL-MID CAP EQUITY (USD)* INVESTMENT OVERVIEW TEAM Name (Years of industry experience) Title David Antonelli (30 yrs.) Portfolio Manager Peter Fruzzetti (24 yrs.) Portfolio
More informationAsia Equity Strategy Research Analysts Sakthi Siva
Asia Pacific Equity Research Investment Strategy Asia Equity Strategy Research Analysts Sakthi Siva 65 6212 3027 sakthi.siva@credit-suisse.com Kin Nang Chik 852 2101 7482 kinnang.chik@credit-suisse.com
More informationNanosonics Limited. Strong start to FY16
Biomedical Devices and Services Australian Equity Research 30 October 2015 BUY unchanged PRICE TARGET unchanged Price (30-Oct) Ticker A$1.95 A$1.64 NAN-ASX 52-Week Range (A$): 0.94-2.02 Avg Daily Vol (000s)
More informationANZ-ROY MORGAN AUSTRALIAN CONSUMER CONFIDENCE MEDIA RELEASE. Figure 1. ANZ-Roy Morgan Australian Consumer Confidence and inflation expectations
ANZ RESEARCH ANZ-ROY MORGAN AUSTRALIAN CONSUMER CONFIDENCE MEDIA RELEASE 17 APRIL 2018 CONTACT research@anz.com CONTRIBUTORS Mustafa Arif Junior Economist +91 80 6795 3801 mustafa.arif@anz.com David Plank
More informationAmbuja Cements. Rating: Target price: EPS: Rating CMP. Target BUY. Rs.225. Rs. 195
: price: EPS: How does our one year outlook change? We maintain our positive stance on ACEM. We expect ACEM to be a big beneficiary of the restructuring of LafargeHolcim s global operations. The long pending
More informationRamco Cement. Rating: Target price: EPS: Rating CMP. Target BUY. Rs.415. Rs. 360
: price: EPS: How does our one year outlook change? We maintain our positive stance on s (TRCL). The company is one of the largest cement producers in South and remains among the best plays on Southern
More informationCMP* (Rs) 336 Upside/ (Downside) (%) 21 Bloomberg Ticker. MOIL IN Market Cap. (Rs bn) 45 Free Float (%) 24 Shares O/S (mn) 133
4QFY17 Result Update June 06, 2017 Market Cap. (Rs bn) 45 Free Float (%) 24 Shares O/S (mn) 133 Mixed Quarterly Performance; Volume to Remain Strong has reported a mixed performance in 4QFY17. Its blended
More informationBUY. White cement steals the show JK CEMENT. Target Price: Rs 1,220. Other highlights
JK 20 NOV 2017 Quarterly Update BUY Target Price: Rs 1,220 White cement steals the show JK Cement s (JKCE) Q2FY18 EBITDA at Rs 2.1 bn (up 30% YoY) was higher than our and consensus estimates, mainly due
More informationDollarama Inc. Q4 F2017 Results. A straight-forward beat and other notable business updates HIGHLIGHTS. The NBF Daily Bulletin.
DOL (T) $110.88 Stock Rating: Outperform (Unchanged) Target: $122.00 (Was $113.00) Risk Rating: Below Average (Unchanged) Est. Total Return: 10.4% Stock Data: 52-week High-Low (Canada) Bloomberg $104.94
More informationBuy Primary Health Properties #
Buy Primary Health Properties # PHP Data Price 107p Target price 125p Market cap 478m Dec 15 EPRA NAV 88p Free float 100% Index FTSE SmallCap Sector Real Estate Next news Aug - Interims UK portfolio 100%
More information2Q 30 JUNE 2018 MFS EUROPEAN VALUE EQUITY (USD)
2Q 30 JUNE 2018 MFS EUROPEAN VALUE EQUITY (USD) INVESTMENT OVERVIEW TEAM Name (Years of industry experience) Title Benjamin Stone (22 yrs.) Portfolio Manager Pablo de la Mata (14 yrs.) Portfolio Manager
More informationManappuram Finance (MGFL IN) Growth picks up in gold loan; Microfinance drive profitability
INSTITUTIONAL EQUITY RESEARCH Manappuram Finance (MGFL IN) Growth picks up in gold loan; Microfinance drive profitability INDIA BFSI Quarterly Update Top takeaways from Q1FY19 Operating results inline
More informationGlobal Property & REIT Quantitative Analysis
Global Property & REIT Quantitative Analysis 4th Quarter 2012 2n S&P Dow Jones Indices Quantitative Analysis Global Property & REIT Page 1 Contents S&P Global Property & REIT 3 S&P Developed Property &
More informationHighlights from the 10-July CoT survey of IMM leveraged funds
Highlights from the 1-July CoT survey of IMM leveraged funds Greg Anderson, CFA, PhD - Global head of FX strategy gregory.anderson@bmo.com +1 212 65 149 July 13, 218 Short-NZD the biggest side with short-eur
More informationANZ-ROY MORGAN AUSTRALIAN CONSUMER CONFIDENCE MEDIA RELEASE. Weekly change, % Four-week average Budget. Budget. Budget. Budget.
Index ANZ RESEARCH ANZ-ROY MORGAN AUSTRALIAN CONSUMER CONFIDENCE MEDIA RELEASE 29 MAY 2018 CONTACT research@anz.com CONTRIBUTORS Mustafa Arif Junior Economist +91 80 6795 3801 mustafa.arif@anz.com David
More informationCONSENSUS OPERATING EARNINGS for the S&P 500, MidCap 400 and SmallCap 600 Indices, as well as the Sectors in the S&P /02/18
CONSENSUS OPERATING EARNINGS for the S&P 500, MidCap 400 and SmallCap 600 Indices, as well as the Sectors in the S&P 500. 02/02/18 Operating EPS Y/Y % chgs. S&P 500 Sector Q1 Q2 2017 Q3 Q4E Year Q1E Q2E
More informationAutoNation, Inc. AN: Company-Specific Headwinds Continue to Weigh on Results, but Cost Controls are Improving
Consumer: Automotive Retail AutoNation, Inc. AN: Company-Specific Headwinds Continue to Weigh on Results, but Cost Controls are Improving Maintaining SW: 1) auto retail industry growth outlook remains
More informationEQUITY RESEARCH. OSFI releases draft of revisions to B-20 mortgage guidelines. For Required Non-U.S. Analyst and Conflicts Disclosures, see page 3.
EQUITY RESEARCH July 7, 2017 Canadian Mortgage Industry OSFI releases draft of revisions to B-20 mortgage guidelines RBC Global Equity Team Click here for contributing analysts' contact information OSFI
More informationKey estimate revision. Financial summary. Year FY14 391,088 45,198 34, FY15E 354,262 35,426 23,
: price: EPS: How does our one year outlook change? We retain our negative stance on the stock. We expect s revenue to de-grow by 9% y-o-y on the back of muted execution (client side and clearance delays)
More information